Comparison of Dopamin Level in Idiopathic Parkinson's Patients

Launched by ANKARA ATATURK SANATORIUM TRAINING AND RESEARCH HOSPITAL · Oct 30, 2023

Keywords

ClinConnect Summary

After more than 40 years of routine clinical use, levodopa has remained the gold standard of symptomatic efficacy in the treatment of Parkinson's disease (PD). Levodopa benserazide and levodopa carbidopa entacapone are antiparkinsonian agents used to treat the motor symptoms of Parkinson's disease.

Parkinson's disease is a neurodegenerative disease characterized by the loss of dopamine-producing neurons in the brain. Dopamine is a neurotransmitter that is central to controlling movement in the brain. Dopamine deficiency leads to motor symptoms typical of Parkinson's disease. These symptoms...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Idiopathic parkinson disease with early stage unilateral manifestations or axial involvement (hoehn yahr stage 1 and 1.5)
• • 40-75 years old years
• • Not taking levodopa preparations in the last 12 hours
• • Not having eaten for at least 2 hours
• • Agreeing to participate in the study
• Exclusion Criteria:
• • Patients under 40 years of age and over 75 years of age
• • Taking levodopa preparations in the last 12 hours
• • Having bilateral, axial involvement
• • Having postural abnormalities
• • Having balance disorders (Hoehn yahr stage 3 and above)
• • Having eaten at least 1 hour ago
• • Not agreeing to participate in the study
• • Body mass index of 35 kg/m2 and above
• • Use of apomorphine, levodopa/carbidopa intestinal gel
• • Applying deep brain stimulation treatment
• • Using a daily dose of levodopa over 800 mg
• • Having dyskinesia
• • Drug-induced parkinsonism
• • Pregnant, postpartum and breastfeeding mothers